Institutional members access full text with Ovid®

Share this article on:

Anorectal Melanoma: Diagnosis and Treatment

Meguerditchian, Ari-Nareg M.D., M.Sc., F.R.C.S.(C.)1; Meterissian, Sarkis H. M.D., M.Sc., F.R.C.S.(C.)1; Dunn, Kelli Bullard M.D.2

Section Editor(s): Dunn, Kelli Bullard

Diseases of the Colon & Rectum: May 2011 - Volume 54 - Issue 5 - p 638-644
doi: 10.1007/DCR.0b013e31820c9b1b
Current Status

An increase in the incidence of anorectal melanoma has recently been noted in the United States. Anorectal melanoma is an uncommon and lethal condition, with a median survival of <20 months. Unfortunately, nonspecific symptoms also attributable to common and benign conditions (eg, hemorrhoids) cause significant delay in its diagnosis. Although it has not been validated by clinical trials, abdominoperineal resection has historically been the treatment of choice for this disease. However, for the past 2 decades, a lack of clear survival benefit has led to a shift toward less-mutilating wide local excisions. Controversy still exists regarding the benefit of radiation therapy and chemotherapy. Furthermore, the value of nodal surgery in anorectal melanoma is unclear. In this article, we review the history and current status of management of anorectal melanoma, with a particular focus on surgical controversies and challenges in optimizing survival.

1Department of Surgery, McGill University, Montreal, Quebec, Canada

2Department of Surgical Oncology, Roswell Park Cancer Institute, and the University at Buffalo, State University of New York, Buffalo, New York

Financial Disclosures: None reported.

Correspondence: Ari-Nareg Meguerditchian, M.D., F.R.C.S.(C.), McGill University Health Centre, 687 Pine Avenue West, Room S10.22, Montreal, Quebec, Canada H3A 1A1. E-mail: ari.meguerditchian@mcgill.ca

© The ASCRS 2011